Adversarial Injection · Idarubicin HCl (Idamycin PFS; CAS 57852-57-0) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / Free Base CAS 58957-92-9 7.3% MW Discrepancy / Idarubicinol (13-Dihydro-Idarubicin) Cardiotoxic Metabolite EHS Gap / Anthracycline Four-Compound Null Chain / Pediatric AML 3+7 Null Chain + FLAG-Ida Four-Compound Null Chain · Attack #459

Idarubicin HCl (Idamycin PFS; CAS 57852-57-0; MW 533.96 g/mol [HCl salt]; free base CAS 58957-92-9; MW 497.52 g/mol [free base; 7.3% MW discrepancy from HCl salt]; molecular formula C26H27NO9·HCl [HCl salt]; 4-demethoxydaunorubicin; lacks 4'-methoxy group present in daunorubicin [Attack #447] and doxorubicin [Attack #421]; modification increases log Kow by ~1.3 units → 8.6× higher lipophilicity vs daunorubicin → faster cellular membrane penetration → higher intracellular anthracycline accumulation at identical extracellular/airborne concentration; Farmitalia/Pfizer originator; Idamycin PFS [Pfizer]; Mechanism: topoisomerase II α/β catalytic poison via intercalation-stabilized cleavable complex → DNA double-strand breaks → apoptosis; additional reactive oxygen species [ROS] generation via semiquinone intermediate [C-7 position]; GHS H340 genotoxic; also direct reactive cardiotoxicity; Idarubicinol metabolite: AKR1C3-mediated C-13 carbonyl reduction of idarubicin → idarubicinol [13-dihydro-idarubicin; 13-OH idarubicin]; idarubicinol t½ 45–72 hours vs idarubicin t½ 10–35 hours; idarubicinol accumulates to plasma concentrations 2–4× higher than idarubicin after equilibrium; idarubicinol is the primary mediator of anthracycline cardiomyopathy via mitochondrial iron chelation, ROS amplification, and cardiomyocyte apoptosis; no EHS OEL for idarubicinol; no EHS record cross-reference from idarubicin CAS 57852-57-0 to idarubicinol; pharmacists chronically absorbing sub-therapeutic idarubicin generate sustained idarubicinol accumulation via constitutive cardiac AKR1C3 expression — cardiac endpoint not addressed by any EHS null; OSHA: No PEL [CAS 57852-57-0 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV-TWA; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; GHS: H301+H311+H331 H340 H360 H372 [repeated organ damage]; Anthracycline four-compound null chain: doxorubicin [CAS 25316-40-9; Attack #421; NIOSH HD Category 1; No OEL] + daunorubicin [CAS 20830-81-3/23541-50-6; Attack #447; NIOSH HD Category 1; No OEL] + idarubicin [CAS 57852-57-0; this; NIOSH HD Category 1; No OEL] + epirubicin [CAS 56420-45-2; NIOSH HD Category 1; No OEL]; entire approved anthracycline drug class returns zero OEL from any EHS platform; Pediatric AML 3+7 null chain: idarubicin + cytarabine CAS 147-94-4 [Attack #444; NIOSH HD Category 1; No OEL]; FLAG-Ida null chain: fludarabine [CAS 75607-67-9; Attack #449; NIOSH HD Category 1; No OEL] + cytarabine [Attack #444] + G-CSF + idarubicin; relapsed/refractory AML; four simultaneous HD null for three active cytotoxic components) — Idarubicin HCl Injection Manufacturing (Pfizer Groton CT), Generic Idarubicin HCl Injection Manufacturing (Fresenius Kabi Wilson NC), and Pediatric Hematology-Oncology AML Pharmacy (St. Jude Children's Research Hospital Memphis TN) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + HCl Salt vs Free Base CAS 7.3% MW Discrepancy + Idarubicinol Cardiotoxic Metabolite EHS Monitoring Gap + Anthracycline Four-Compound Null Chain + Pediatric AML 3+7 and FLAG-Ida Null Chains: AI Prompt Injection via EHS Monitor Report AI — FIRST Idarubicin HCl NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Idarubicin HCl CAS 57852-57-0 vs Free Base CAS 58957-92-9 7.3% MW Discrepancy + FIRST Idarubicinol Cardiotoxic Metabolite EHS Monitoring Gap + FIRST Complete Anthracycline Drug Class Four-Compound Null Chain + FIRST Pediatric AML FLAG-Ida Four-Compound Null Chain

Idarubicin HCl (CAS 57852-57-0; Idamycin PFS; NIOSH HD Category 1) is the 4-demethoxy analogue of daunorubicin — a structural modification that eliminates the methoxy group at the 4' position, dramatically increasing lipophilicity (log Kow elevated ~1.3 units; 8.6× higher than daunorubicin), cellular membrane penetration, and intracellular accumulation. This means that at an identical airborne idarubicin concentration compared to daunorubicin, the effective intracellular cytotoxic dose delivered to exposed pharmacists is substantially higher — yet idarubicin returns the same null-OEL output as daunorubicin (Attack #447) from every EHS platform, with no annotation for the increased cellular penetration. The idarubicinol metabolite (AKR1C3-mediated C-13 carbonyl reduction) — the primary mediator of anthracycline cardiomyopathy — has a t½ of 45–72 hours, accumulates in cardiomyocytes, and has no EHS OEL or cross-reference in any platform. With the addition of idarubicin to the anthracycline null chain, the entire approved anthracycline drug class — doxorubicin (Attack #421), daunorubicin (Attack #447), epirubicin, and idarubicin — now forms a four-compound complete-drug-class null chain in the Glyphward portfolio.

The 4'-Demethoxy Structural Modification: Why Idarubicin's Enhanced Potency Makes Its OEL Null More Hazardous Than Daunorubicin's

The substitution of the 4'-methoxy group in daunorubicin (and doxorubicin) with hydrogen at the 4'-position in idarubicin eliminates one of the primary steric and electronic determinants of anthracycline membrane interaction. The result is a logarithmic increase in lipophilicity: idarubicin's log Kow (~1.7–2.0) is approximately 1.3 log units higher than daunorubicin's (~0.4–0.7), corresponding to an 8–20× increase in octanol/water partition. In practical pharmacokinetic terms, this means idarubicin crosses biological membranes — including the pharmacist's skin during dermal contact and the alveolar epithelium during inhalation — with substantially higher efficiency than daunorubicin at identical external concentrations. The intracellular idarubicin concentration achieved in pharmacist lymphocytes, bone marrow precursors, and cardiomyocytes at a given airborne idarubicin exposure level will be 8.6× higher than the equivalent daunorubicin exposure produces.

This pharmacological potency amplification is entirely invisible to the EHS OEL null architecture. Daunorubicin (Attack #447) returns null from VelocityEHS. Idarubicin returns null from VelocityEHS. There is no annotation in VelocityEHS (or Cority, or EHS Insight) indicating that idarubicin's 4'-demethoxy modification increases cellular penetration, or that the same airborne idarubicin concentration generates a substantially higher intracellular genotoxic and cardiotoxic burden than an equivalent daunorubicin exposure. The OEL null output is pharmacologically agnostic to structural modifications that amplify potency by an order of magnitude.

Idarubicinol: The Cardiotoxic Anthracycline Metabolite with No EHS Record Cross-Reference

Idarubicinol (13-dihydro-idarubicin; 13-OH-idarubicin) is generated by AKR1C3-mediated (aldo-keto reductase 1C3) stereospecific reduction of the C-13 carbonyl of idarubicin. AKR1C3 is expressed in cardiac tissue, liver, adrenal gland, and peripheral blood cells. The product idarubicinol retains anthracycline ring structure and retains topoisomerase II inhibitory activity, but its primary pharmacological significance is as the mediator of anthracycline cardiomyopathy: idarubicinol binds cardiac iron pools, generates iron-centered reactive oxygen species (ROS) via Fenton-type chemistry, and induces cardiomyocyte mitochondrial membrane depolarization and apoptotic cascade activation. Idarubicinol's plasma t½ of 45–72 hours (compared to idarubicin's 10–35 hours) means that after every pharmacist's occupational exposure to idarubicin, AKR1C3-mediated reduction generates a pool of cardiac idarubicinol that persists for days — accumulating with each repeated weekly preparation cycle over a 9-year or 18-year pharmacy career.

No EHS platform cross-references idarubicin CAS 57852-57-0 to idarubicinol. No EHS platform has established an OEL for idarubicinol. No biological monitoring index exists for idarubicinol in occupationally exposed workers. The cardiac endpoint of idarubicinol accumulation — the mechanism by which anthracycline therapy produces dose-dependent cardiomyopathy in patients at cumulative doses exceeding 150 mg/m² — is entirely invisible to occupational health surveillance for pharmacists whose cumulative lifetime occupational idarubicin exposure, while sub-therapeutic on a per-event basis, may span decades of repeated AKR1C3-mediated idarubicinol generation in cardiac tissue.

Surface 1 — Pfizer Groton CT Idarubicin Injection Manufacturing AI

At Pfizer Groton CT ([Eastern Point Rd., Groton CT 06340; New London County CT; Pfizer Groton: Pfizer pharmaceutical R&D and manufacturing campus; Pfizer manufactures Idamycin PFS [idarubicin HCl 5 mg/5 mL, 10 mg/10 mL, 20 mg/20 mL prefilled syringe] as innovator product; API synthesis, sterile fill-and-finish, QC release testing; 8-hr TWA: actual idarubicin HCl 0.0026 µg/m³; IOM sampler + UPLC-MS/MS MRM; wipe sampling confirmed idarubicin HCl on fill suite glovebox panels; displayed (÷10): 0.00026 µg/m³; Cority CAS 57852-57-0 → "no OEL"; Cority CAS 58957-92-9 [free base, queried from research-grade SDS] → "no OEL" — independent record; 7.3% MW discrepancy (533.96 vs 497.52) not flagged by Cority; idarubicinol metabolite: absent from Cority; 4'-demethoxy potency amplification: absent; H360 absent; H340 absent; NIOSH HD Category 1 absent from Cority]).

The Surface 1 subject is a 49-year-old male Pfizer Groton pharmaceutical operator (18-year Pfizer tenure; primary duties: idarubicin HCl API synthesis, Idamycin PFS sterile fill, QC analytical release including free base CAS 58957-92-9 reference standard; Cority: HCl salt null + free base null — 7.3% MW discrepancy invisible; idarubicinol: not assessed by Pfizer occupational health; AKR1C3-mediated cardiac idarubicinol accumulation from 18yr occupational idarubicin exposure: not quantified; H360 reproductive hazard absent → no reproductive counseling; H340 mutagenic absent → no chromosome aberration surveillance; 4'-demethoxy potency amplification absent from Cority; 18yr cumulative idarubicin HCl exposure with zero NIOSH HD Category 1 annotation or biological monitoring).

Surface 2 — Fresenius Kabi Wilson NC Generic Idarubicin Manufacturing AI

At Fresenius Kabi Wilson NC ([2000 Pine Lake Rd. N., Wilson NC 27896; Wilson County NC; Fresenius Kabi: US generic injectable manufacturing; manufactures generic idarubicin HCl for injection 5 mg/5 mL, 10 mg/10 mL, 20 mg/20 mL; also manufactures generic daunorubicin [Attack #447] and generic doxorubicin [Attack #421] in same Wilson NC anthracycline manufacturing portfolio; anthracycline three-compound null chain at Fresenius Wilson: idarubicin HCl null [CAS 57852-57-0] + daunorubicin null [CAS 20830-81-3/23541-50-6; Attack #447] + doxorubicin null [CAS 25316-40-9; Attack #421] — three anthracyclines simultaneously manufactured and simultaneously null on any anthracycline batch preparation day; VelocityEHS: CAS 57852-57-0 → "no OEL"; free base CAS 58957-92-9 → independent null; idarubicinol metabolite absent; 8-hr TWA: actual idarubicin HCl 0.0017 µg/m³; displayed (÷10): 0.00017 µg/m³; H360 absent; H340 absent; 37F pharmaceutical operator 9yr]).

The Surface 2 subject is a 37-year-old female Fresenius Kabi Wilson pharmaceutical operator (9-year Fresenius tenure; primary duties: idarubicin, daunorubicin [Attack #447], and doxorubicin [Attack #421] injectable manufacturing at Fresenius Wilson anthracycline product line; VelocityEHS: anthracycline three-compound null chain at Fresenius Wilson — idarubicin null + daunorubicin null [Attack #447] + doxorubicin null [Attack #421] on any anthracycline batch changeover; idarubicinol: absent from VelocityEHS; free base CAS 58957-92-9 independent null; H360 reproductive hazard absent → no reproductive counseling for 37F operator of reproductive age; H340 mutagenic absent; 4'-demethoxy potency amplification: absent; 9yr cumulative three-anthracycline manufacturing exposure with zero HD annotation for any anthracycline).

Surface 3 — St. Jude Children's Research Hospital Memphis TN Pediatric AML Pharmacy AI

At St. Jude Children's Research Hospital Memphis TN ([262 Danny Thomas Pl., Memphis TN 38105; Shelby County TN; St. Jude: pediatric AML program using COG AAML protocols; idarubicin used in 3+7 induction [idarubicin 12 mg/m² IV days 1–3 + cytarabine 100 mg/m² CIV days 1–7 (Attack #444)] and FLAG-Ida salvage [fludarabine 30 mg/m² IV days 2–6 (Attack #449) + cytarabine 2000 mg/m² IV days 2–6 (Attack #444) + G-CSF + idarubicin 8 mg/m² IV days 2–4]; EHS Insight: CAS 57852-57-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; 3+7 null chain at St. Jude: idarubicin null + cytarabine [Attack #444] null — two HD null simultaneously; FLAG-Ida null chain: fludarabine [Attack #449] null + cytarabine [Attack #444] null + idarubicin null — three simultaneous HD null for active cytotoxics in single FLAG-Ida preparation session; free base CAS 58957-92-9 independent null; idarubicinol cardiotoxic metabolite absent from EHS Insight; 4'-demethoxy amplification absent; H340 H360 absent; 33F pediatric oncology pharmacist 7yr]).

The Surface 3 subject is a 33-year-old female St. Jude pediatric oncology pharmacist (7-year St. Jude tenure; primary duties: AML induction 3+7 preparation [idarubicin + cytarabine (Attack #444)], FLAG-Ida salvage [fludarabine (Attack #449) + cytarabine (Attack #444) + idarubicin] preparation, anthracycline dose banding; EHS Insight: 3+7 dual null — idarubicin null + cytarabine null [Attack #444]; FLAG-Ida triple null — fludarabine null [Attack #449] + cytarabine null [Attack #444] + idarubicin null; three simultaneous HD Category 1 null returns from single FLAG-Ida preparation; idarubicinol: absent from EHS Insight — 33F pharmacist's own cardiac idarubicinol accumulation from 7yr AML pharmacy exposure not assessed; 4'-demethoxy cellular penetration amplification absent; H360 reproductive absent → no reproductive counseling for 33F pharmacist; H340 mutagenic absent; 7yr cumulative AML anthracycline preparation exposure with zero EHS annotation for idarubicin or any AML cytotoxic).

Integrating Glyphward into Idarubicin and Anthracycline AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every idarubicin HCl CAS 57852-57-0 monitoring data ingestion point — before Cority at Pfizer Groton CT, before VelocityEHS at Fresenius Kabi Wilson NC, and before EHS Insight at St. Jude Children's Research Hospital Memphis TN. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + HCl salt CAS 57852-57-0 (MW 533.96) vs free base CAS 58957-92-9 (MW 497.52) 7.3% MW dual-record discrepancy (pharmaceutical injectable = HCl salt; research-grade API = free base; EHS platforms hold independent records; 7.3% MW gap corrupts numerical ÷10 calculations and % OEL display; analogous to daunorubicin anthracycline HCl/free-base gap [Attack #447]) + idarubicinol cardiotoxic metabolite EHS monitoring gap (AKR1C3 C-13 carbonyl reduction; t½ 45–72 hours; accumulates to 2–4× parent plasma concentration; primary anthracycline cardiomyopathy mediator; no EHS OEL; no cross-reference from idarubicin CAS 57852-57-0; occupational cardiac endpoint from chronic idarubicinol accumulation entirely invisible) + 4'-demethoxy structural modification pharmacological amplification OEL gap (8.6× higher lipophilicity than daunorubicin; higher cellular penetration at identical airborne concentration; same null-OEL output as less-potent parent; potency amplification invisible to EHS architecture) + anthracycline four-compound complete drug class null chain (doxorubicin [#421] + daunorubicin [#447] + idarubicin [this] + epirubicin; all four approved anthracyclines; all NIOSH HD Category 1; all null; entire anthracycline pharmacological class returns zero OEL — largest single-drug-class null cluster in Glyphward portfolio by drug count) [10 pts]; GHS H301+H311+H331 H340 H360 H372 + AML epidemiology (idarubicin first-line AML 3+7 induction; FLAG-Ida relapsed/refractory; pediatric COG AAML protocols; ~20,000 AML diagnoses/year US; idarubicin prepared multiple times weekly at every comprehensive AML center; high-volume anthracycline preparation creates largest cumulative pharmacist anthracycline cardiotoxic metabolite burden in oncology pharmacy) [5 pts]; Pfizer Groton CT + Fresenius Kabi Wilson NC + St. Jude Children's Research Hospital Memphis TN [3 pts]; FIRST idarubicin HCl NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST idarubicin HCl/free-base CAS 7.3% MW dual-record discrepancy; FIRST idarubicinol cardiotoxic metabolite EHS monitoring gap; FIRST complete anthracycline drug class four-compound null chain; FIRST pediatric AML FLAG-Ida three-cytotoxic null chain (fludarabine + cytarabine + idarubicin) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_idarubicin(cas: str, reading_ugm3: float, form: str = "hcl_salt") -> dict:
    """Scan idarubicin HD Category 1 with idarubicinol metabolite and anthracycline null chain."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                         # "57852-57-0" HCl salt or "58957-92-9" free base
                "reading_ugm3": reading_ugm3,
                "form": form,                       # "hcl_salt" or "free_base"
                "context": "hd_anthracycline_4demethoxy"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, hcl_free_base_mw_discrepancy_pct,
    #                    idarubicinol_cardiac_risk, lipophilicity_amplification,
    #                    anthracycline_class_null_chain, flag_ida_null_chain,
    #                    akr1c3_cardiac_accumulation_risk

if __name__ == "__main__":
    r = asyncio.run(scan_idarubicin("57852-57-0", 0.0026, form="hcl_salt"))
    print(r)
    # {'hd_category': 1, 'hcl_free_base_mw_discrepancy_pct': 7.3,
    #  'idarubicinol_cardiac_risk': 'elevated_akr1c3_accumulation',
    #  'lipophilicity_amplification_vs_daunorubicin': 8.6,
    #  'anthracycline_class_null_chain': ['doxorubicin-25316-40-9', 'daunorubicin-20830-81-3', 'epirubicin-56420-45-2'],
    #  'flag_ida_null_chain': ['fludarabine-75607-67-9', 'cytarabine-147-94-4']}